Half-Life Cancer Research Results

Half-Life, Half-Life: Click to Expand ⟱
Source:
Type:
For many drugs, the half-life is the time it takes for half of the drug’s active substance to be eliminated from the bloodstream.
In medicine, knowing a drug’s half-life helps in designing treatment regimens that reduce adverse effects.
Var, Various Cancer: Click to Expand ⟱
Cyclooxygenase (COX)-2 overexpression has been noted in various cancers. PI3Ks/AKT pathways are over-activated in several types of cancers.
EGFR altered activity has been noted in various pathological conditions. However, its regulation is an important step in the inhibition of cancer. In this regard, EGCG shows a pivotal role in the inhibition of EGFR activity.
Activating protein-1 transcription factor has been associated with pathogenesis including cancer.
Activation of the sonic hedgehog (Shh) pathway is required for the growth of numerous tissues and organs and recent evidence indicates that this pathway is often recruited to stimulate growth of cancer stem cells (CSCs) and to orchestrate the reprogramming of cancer cells via epithelial mesenchymal transition (EMT). Increased expression of Nanog has been associated with the aggressive nature of certain cancers, highlighting its role in promoting cancer stem cell characteristics.
The aberrant hedgehog (Hh)/GLI signaling pathway causes the formation and progression of a variety of tumors.
The process of cell apoptosis is often accompanied by the destruction of mitochondrial transmembrane potential, which is widely regarded as one of the earliest events in the process of cell apoptosis.
Human malignancies frequently exhibit mutations in the TGF-β pathway, and overactivation of this system is linked to tumor growth by promoting angiogenesis and inhibiting the innate and adaptive antitumor immune responses50.
Several studies have demonstrated that high cyclin D1 expression was observed in cancers including breast, lung, prostate, lymph node and colorectal cancers [23–25].
The oncogene c-myc, which is frequently over-expressed in cancer cells, is involved in the transactivation of most of the glycolytic enzymes including lactate dehydrogenase A (LDHA) and the glucose transporter GLUT1 [51,52]. Thus, c-myc activation is a likely candidate to promote the enhanced glucose uptake and lactate release in the proliferating cancer cell.
Vimentin is overexpressed in various epithelial cancers, including prostate cancer, gastrointestinal tumors, tumors of the central nervous system, breast cancer, malignant melanoma, and lung cancer. Vimentin’s overexpression in cancer correlates well with accelerated tumor growth, invasion, and poor prognosis; however, the role of vimentin in cancer progression remains obscure.
Heat shock proteins (HSPs) are normally induced under environmental stress to serve as chaperones for maintenance of correct protein folding but they are often overexpressed in many cancers, including breast cancer.
Since NQO1 is highly expressed in many solid tumors, including via upregulation of Nrf2, the design of compounds activated by NQO1 and NQO1-targeted drug delivery have been active areas of research.
Since increased Nrf2 gene expression is one of the main mechanisms of cancer cells in resisting chemotherapeutic drugs and survival in oxidative conditions; finding compounds with the ability to suppress Nrf2 gene expression with minimum side effects can be considered an important strategy for increasing the sensitivity of cancer cells to chemotherapy.
Overexpression of c-met stimulates proliferation, migration and invasion in various types of cancer including prostate cancer.
Overexpression of TGFα and EGFR by many carcinomas correlates with the development of cancer metastasis, resistance to chemotherapy and poor prognosis.
More than 50% of human cancers have a mutated nonfunctional p53.


Scientific Papers found: Click to Expand⟱
5355- AL,    Mini-review: The health benefits and applications of allicin
- Review, Var, NA
*BioAv↑, *cardioP↑, *hepatoP↑, *RenoP↑, *Half-Life↝, *BioAv↓, *neuroP↑, *cognitive↑, *ROS↓, *lipid-P↓, *DNArepair↑, *ChemoSen↑,
2660- AL,    Allicin: A review of its important pharmacological activities
- Review, AD, NA - Review, Var, NA - Review, Park, NA - Review, Stroke, NA
*Inflam↓, AntiCan↑, *antiOx↑, *cardioP↑, *hepatoP↑, *BBB↑, *Half-Life↝, *H2S↑, *BP↓, *neuroP↑, *cognitive↑, *neuroP↑, *ROS↓, *GutMicro↑, *LDH↓, *ROS↓, *lipid-P↓, *antiOx↑, *other↑, *PI3K↓, *Akt↓, *NF-kB↓, *NO↓, *iNOS↓, *PGE2↓, *COX2↓, *IL6↓, *TNF-α↓, *MPO↓, *eff↑, *NRF2↑, *Keap1↓, *TBARS↓, *creat↓, *LDH↓, *AST↓, *ALAT↓, *MDA↓, *SOD↑, *GSH↑, *GSTs↑, *memory↑, chemoP↑, IL8↓, Cyt‑c↑, Casp3↑, Casp8↑, Casp9↑, Casp12↑, p38↑, Fas↑, P53↑, P21↑, CHK1↓, CycB/CCNB1↓, GSH↓, ROS↑, TumCCA↑, Hif1a↓, Bcl-2↓, VEGF↓, TumCMig↓, STAT3↓, VEGFR2↓, p‑FAK↓,
3155- Ash,    Overview of the anticancer activity of withaferin A, an active constituent of the Indian ginseng Withania somnifera
- Review, Var, NA
Half-Life↝, Inflam↓, antiOx↓, angioG↓, ROS↑, BAX↑, Bak↑, E6↓, E7↓, P53↑, Casp3↑, cl‑PARP↑, STAT3↓, eff↑, HSP90↓, TGF-β↓, TNF-α↓, EMT↑, mTOR↓, NOTCH1↓, p‑Akt↓, NF-kB↓, Dose↝,
3166- Ash,    Exploring the Multifaceted Therapeutic Potential of Withaferin A and Its Derivatives
- Review, Var, NA
*p‑PPARγ↓, *cardioP↑, *AMPK↑, *BioAv↝, *Half-Life↝, *Half-Life↝, *Dose↑, *chemoPv↑, IL6↓, STAT3↓, ROS↓, OXPHOS↓, PCNA↓, LDH↓, AMPK↑, TumCCA↑, NOTCH3↓, Akt↓, Bcl-2↓, Casp3↑, Apoptosis↑, eff↑, NF-kB↓, CSCs↓, HSP90↓, PI3K↓, FOXO3↑, β-catenin/ZEB1↓, N-cadherin↓, EMT↓, FASN↓, ACLY↓, ROS↑, NRF2↑, HO-1↑, NQO1↑, JNK↑, mTOR↓, neuroP↑, *TNF-α↓, *IL1β↓, *IL6↓, *IL8↓, *IL18↓, RadioS↑, eff↑,
2716- BetA,    Cellular and molecular mechanisms underlying the potential of betulinic acid in cancer prevention and treatment
- Review, Var, NA
AntiCan↑, TumCD↑, TumCCA↑, ROS↑, NF-kB↓, Bcl-2↓, Half-Life↝, GLUT1↓, VEGF↓, PDK1↓,
5825- CAP,    Bioavailability of capsaicin and its implications for drug delivery
- Review, Var, NA - Review, Arthritis, NA - Review, Obesity, NA
*AntiCan↑, *TRPV1↑, *cardioP↑, AntiCan↓, Apoptosis↑, ChemoSen↑, *Inflam↓, *Pain↓, *AntiAg↑, *Weight↓, *BioAv↑, BioAv↑, Half-Life↝, Half-Life↓,
5811- CBC,    The Potential of Cannabichromene (CBC) as a Therapeutic Agent
- Review, Var, NA
*eff?, *Half-Life↝, *Inflam↓,
2824- FIS,    Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics
- Review, Var, NA
*antiOx↑, *Inflam↓, angioG↓, BioAv↓, BioAv↑, TumCP↓, TumCI↓, TumCMig↓, *neuroP↑, EMT↓, ROS↑, selectivity↑, EGFR↓, NF-kB↓, VEGF↓, MMP9↓, MMP↓, cl‑PARP↑, Casp7↑, Casp8↑, Casp9↑, *ROS↓, uPA↓, MMP1↓, Wnt↓, Akt↓, PI3K↓, ERK↓, Half-Life↝,
2825- FIS,    Exploring the molecular targets of dietary flavonoid fisetin in cancer
- Review, Var, NA
*Inflam↓, *antiOx↓, *ERK↑, *p‑cMyc↑, *NRF2↑, *GSH↑, *HO-1↑, mTOR↓, PI3K↓, Akt↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, P21↑, p27↑, JNK↑, MMP2↓, MMP9↓, uPA↓, NF-kB↓, cFos↓, cJun↓, E-cadherin↑, Vim↓, N-cadherin↓, EMT↓, MMP↓, Cyt‑c↑, Diablo↑, Casp↑, cl‑PARP↑, P53↑, COX2↓, PGE2↓, HSP70/HSPA5↓, HSP27↓, DNAdam↑, Casp3↑, Casp9↑, ROS↑, AMPK↑, NO↑, Ca+2↑, mTORC1↓, p70S6↓, ROS↓, ER Stress↑, IRE1↑, ATF4↑, GRP78/BiP↑, eff↑, eff↑, eff↑, RadioS↑, ChemoSen↑, Half-Life↝,
2864- HNK,    Honokiol: A Review of Its Anticancer Potential and Mechanisms
- Review, Var, NA
TumCCA↑, CDK2↓, EMT↓, MMPs↓, AMPK↑, TumCI↓, TumCMig↓, TumMeta↓, VEGFR2↓, *antiOx↑, *Inflam↓, *BBB↑, *neuroP↑, *ROS↓, Dose↝, selectivity↑, Casp3↑, Casp9↑, NOTCH1↓, cycD1/CCND1↓, cMyc↓, P21?, DR5↑, cl‑PARP↑, P53↑, Mcl-1↑, p65↓, NF-kB↓, ROS↑, JNK↑, NRF2↑, cJun↑, EF-1α↓, MAPK↓, PI3K↓, mTORC1↓, CSCs↓, OCT4↓, Nanog↓, SOX4↓, STAT3↓, CDK4↓, p‑RB1↓, PGE2↓, COX2↓, β-catenin/ZEB1↑, IKKα↓, HDAC↓, HATs↑, H3↑, H4↑, LC3II↑, c-Raf↓, SIRT3↑, Hif1a↓, ER Stress↑, GRP78/BiP↑, cl‑CHOP↑, MMP↓, PCNA↓, Zeb1↓, NOTCH3↓, CD133↓, Nestin↓, ATG5↑, ATG7↑, survivin↓, ChemoSen↑, SOX2↓, OS↑, P-gp↓, Half-Life↓, Half-Life↝, eff↑, BioAv↓,
2180- itraC,    Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent
- Review, Var, NA
Dose↝, toxicity↝, BioAv↑, Half-Life↝, BioAv↑, Dose↝, HH↓, TumAuto↑, Akt↓, mTOR↓, angioG↓, MDR1↓, TumCP↓, eff↑,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
4643- OLE,  HT,    Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine
- Review, Var, NA
TumCCA↑, Apoptosis↑, ER Stress↑, UPR↑, CHOP↑, ROS↑, Bcl-2↓, NOX4↑, Hif1a↓, MMP2↓, MMP↓, VEGF↓, Akt↓, NF-kB↓, p65↓, SIRT3↓, mTOR↓, Catalase↓, SOD2↓, FASN↓, STAT3↓, HDAC2↓, HDAC3↓, BAD↑, BAX↑, Bak↑, Casp3↑, Casp9↑, PARP↑, P53↑, P21↑, p27↑, Half-Life↝, BioAv↓, BioAv↓, selectivity↑, RadioS↑, *ROS↓, *GSH↑, *MDA↓, *SOD↑, *Catalase↑, *NRF2↑, *chemoP↑, *Inflam↓, PPARγ↑,
4922- PEITC,    Phenethyl Isothiocyanate: A comprehensive review of anti-cancer mechanisms
- Review, Var, NA
Risk↓, AntiCan↑, TumCP↓, TumMeta↓, ChemoSen↑, *BioAv↑, *other↝, *Dose↝, Dose↓, *BioAv↑, *Dose↝, *Half-Life↝, *toxicity↝, GSH↓, ROS↑, CYP1A1↑, CYP1A2↑, P450↓, CYP2E1↑, CYP3A4↓, CYP2A3/CYP2A6↓, *ROS↓, *GPx1↑, *SOD1↑, *SOD2↑, Akt↓, EGFR↓, HER2/EBBR2↓, P53↑, Telomerase↓, selectivity↑, MMP↓, Cyt‑c↑, Apoptosis↑, DR4↑, Fas↑, XIAP↓, survivin↓, TumAuto↑, Hif1a↓, angioG↓, MMPs↓, ERK↓, NF-kB↓, EMT↓, TumCI↓, TumCMig↓, Glycolysis↓, ATP↓, selectivity↑, *antiOx↑, Dose↝, other↝, OCR↓, GSH↓, ITGB1↓, ITGB6↓, ChemoSen↑,
2946- PL,    Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent
- Review, Var, NA
ROS↑, GSH↓, DNAdam↑, ChemoSen↑, RadioS↑, BioEnh↑, selectivity↑, BioAv↓, eff↑, p‑Akt↓, mTOR↓, GSK‐3β↓, β-catenin/ZEB1↓, HK2↓, Glycolysis↓, Cyt‑c↑, Casp9↑, Casp3↑, Casp7↑, cl‑PARP↑, TrxR↓, ER Stress↑, ATF4↝, CHOP↑, Prx4↑, NF-kB↓, cycD1/CCND1↓, CDK4↓, CDK6↓, p‑RB1↓, RAS↓, cMyc↓, TumCCA↑, selectivity↑, STAT3↓, NRF2↑, HO-1↑, PTEN↑, P-gp↓, MDR1↓, MRP1↓, survivin↓, Twist↓, AP-1↓, Sp1/3/4↓, STAT1↓, STAT6↓, SOX4↑, XBP-1↑, P21↑, eff↑, Inflam↓, COX2↓, IL6↓, MMP9↓, TumMeta↓, TumCI↓, ICAM-1↓, CXCR4↓, VEGF↓, angioG↓, Half-Life↝, BioAv↑,
3055- RES,    Resveratrol and Tumor Microenvironment: Mechanistic Basis and Therapeutic Targets
- Review, Var, NA
BioAv↓, BioAv↓, Dose↑, eff↑, eff↑, Dose↑, BioAv↑, ROS↑, MMP↓, P21↑, p27↑, TumCCA↑, ChemoSen↑, COX2↓, 5LO↓, VEGF↓, IL1↓, IL6↓, IL8↓, AR↓, PSA↓, MAPK↓, Hif1a↓, Glycolysis↓, miR-21↓, PTEN↑, Half-Life↝, *IGF-1↓, *IGFBP3↑, Half-Life↓,
3063- RES,    Resveratrol: A Review of Pre-clinical Studies for Human Cancer Prevention
- Review, Var, NA
*Inflam↓, *antiOx↑, *AntiAg↑, *chemoPv↑, ChemoSen↑, BioAv↑, Half-Life↝, COX2↓, cycD1/CCND1↓, CDK2↓, CDK4↓, CDK6↓, P21↑, MMP9↓, NF-kB↓, Telomerase↓, PSA↓, MAPK↑, P53↑,
1744- RosA,    Therapeutic Applications of Rosmarinic Acid in Cancer-Chemotherapy-Associated Resistance and Toxicity
- Review, Var, NA
chemoR↓, ChemoSideEff↓, RadioS↑, ROS↓, ChemoSen↑, BioAv↑, Half-Life↝, antiOx↑, ROS↑, Fenton↑, DNAdam↑, Apoptosis↑, CSCs↓, HH↓, Bax:Bcl2↑, MDR1↓, P-gp↓, eff↑, eff↑, FOXO4↑, *eff↑, *ROS↓, *JNK↓, *ERK↓, *GSH↑, *H2O2↑, *MDA↓, *SOD↑, *HO-1↑, *CardioT↓, selectivity↑,
2549- SDT,    Landscape of Cellular Bioeffects Triggered by Ultrasound-Induced Sonoporation
- Review, Var, NA
sonoP↑, tumCV↓, MMP↓, ROS↑, Ca+2↑, eff↝, eff↑, selectivity↑, Half-Life↝, Dose↝, P-gp↓, ER Stress↑, other↑,
3293- SIL,    Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer
- Review, Var, NA
hepatoP↑, TumMeta↓, Inflam↓, chemoP↑, radioP↑, Half-Life↝, *GSTs↑, p‑JNK↑, BAX↑, p‑p38↑, cl‑PARP↑, Bcl-2↓, p‑ERK↓, TumVol↓, eff↑, TumCCA↑, STAT3↓, Mcl-1↓, survivin↓, Bcl-xL↓, Casp3↑, Casp9↑, eff↑, CXCR4↓, Dose↝,
3041- SK,    Promising Nanomedicines of Shikonin for Cancer Therapy
- Review, Var, NA
Glycolysis↓, TAMS↝, BioAv↓, Half-Life↝, P21↑, ERK↓, ROS↑, GSH↓, MMP↓, TrxR↓, MMP13↓, MMP2↓, MMP9↓, SIRT2↑, Hif1a↓, PKM2↓, TumCP↓, TumMeta↓, TumCI↓,
3040- SK,    Pharmacological Properties of Shikonin – A Review of Literature since 2002
- Review, Var, NA - Review, IBD, NA - Review, Stroke, NA
*Half-Life↝, *BioAv↓, *BioAv↑, *BioAv↑, *Inflam↓, *TNF-α↓, *other↑, *MPO↓, *COX2↓, *NF-kB↑, *STAT3↑, *antiOx↑, *ROS↓, *neuroP↑, *SOD↑, *Catalase↑, *GPx↑, *Bcl-2↑, *BAX↓, cardioP↑, AntiCan↑, NF-kB↓, ROS↑, PKM2↓, TumCCA↑, Necroptosis↑, Apoptosis↑, DNAdam↑, MMP↓, Cyt‑c↑, LDH↝,
5073- SSE,    Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study
- Trial, Var, NA
AntiTum↑, ChemoSen↑, Dose↑, Half-Life↝, toxicity↝, toxicity↝,
5085- SSE,    Intravenous Infusion of High Dose Selenite in End-Stage Cancer Patients: Analysis of Systemic Exposure to Selenite and Seleno-Metabolites
- Review, Var, NA
toxicity↝, Half-Life↝, ROS↑, Thiols↓, NADPH↓, toxicity↝, other↝,
2084- TQ,    Thymoquinone, as an anticancer molecule: from basic research to clinical investigation
- Review, Var, NA
*ROS↓, *chemoPv↑, ROS↑, ROS⇅, MUC4↓, selectivity↑, AR↓, cycD1/CCND1↓, Bcl-2↓, Bcl-xL↓, survivin↓, Mcl-1↓, VEGF↓, cl‑PARP↑, ROS↑, HSP70/HSPA5↑, P53↑, miR-34a↑, Rac1↓, TumCCA↑, NOTCH↓, NF-kB↓, IκB↓, p‑p65↓, IAP1↓, IAP2↑, XIAP↓, TNF-α↓, COX2↓, Inflam↓, α-tubulin↓, Twist↓, EMT↓, mTOR↓, PI3K↓, Akt↓, BioAv↓, ChemoSen↑, BioAv↑, PTEN↑, chemoPv↑, RadioS↑, *Half-Life↝, *BioAv↝,
5904- TV,    Pharmacological Properties and Molecular Mechanisms of Thymol: Prospects for Its Therapeutic Potential and Pharmaceutical Development
- Review, Var, NA - Review, Stroke, NA - Review, Diabetic, NA - Review, Obesity, NA - Review, AD, NA - Review, Arthritis, NA
*antiOx↑, *ROS↓, *Inflam↓, *Bacteria↓, AntiTum↑, IronCh↑, *HDL↑, *LDL↓, *BioAv↝, *Half-Life↝, *BioAv↑, *SOD↑, *GPx↑, *GSTs↑, *eff↑, radioP↑, *MDA↓, *other↑, *COX1↓, *COX2↓, *AntiAg↑, *RNS↓, *NO↓, *H2O2↓, *NOS2↓, *NADH↓, *Imm↑, Apoptosis↑, TumCP↓, angioG↓, TumCMig↓, Ca+2↑, TumCCA↑, DNAdam↑, BAX↑, Casp9↑, Casp8↑, Casp3↑, cl‑PARP↑, AIF↑, i-ROS↑, MMP↓, Cyt‑c↑, APAF1↑, Ca+2↑, MMP9↓, MMP2↓, PKCδ↓, ERK↓, H2O2↑, BAX↑, Bcl-2↓, DNAdam↑, lipid-P↑, ChemoSen↑, chemoP↑, *cardioP↑, *SOD↑, *Catalase↑, *GPx↑, *GSH↑, *BP↓, *AntiDiabetic↑, *Obesity↓, RenoP↑, *GastroP↑, hepatoP↑, *AChE↓, *cognitive↑, *BChE↓, *other↓, *BioAv↑,

Showing Research Papers: 1 to 26 of 26

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 26

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 1,   Catalase↓, 2,   CYP1A1↓, 1,   CYP1A1↑, 1,   CYP2E1↑, 1,   Fenton↑, 1,   GPx↓, 1,   GSH↓, 7,   GSR↓, 1,   GSTs↓, 1,   H2O2↑, 1,   HO-1↓, 1,   HO-1↑, 2,   lipid-P↑, 1,   NOX4↑, 1,   NQO1↓, 1,   NQO1↑, 1,   NRF2↓, 1,   NRF2↑, 3,   OXPHOS↓, 1,   Prx4↑, 1,   ROS↓, 3,   ROS↑, 19,   ROS⇅, 1,   i-ROS↑, 1,   SIRT3↓, 1,   SIRT3↑, 1,   SOD↓, 1,   SOD2↓, 2,   Thiols↓, 1,   TrxR↓, 2,   VitC↓, 1,   VitE↓, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 2,   ATP↓, 1,   MMP↓, 10,   OCR↓, 1,   c-Raf↓, 1,   XIAP↓, 3,  

Core Metabolism/Glycolysis ⓘ

ACLY↓, 1,   AMPK↑, 3,   ATG7↑, 1,   cMyc↓, 2,   CYP3A4↓, 1,   FASN↓, 2,   Glycolysis↓, 4,   HK2↓, 1,   LDH↓, 1,   LDH↝, 1,   NADPH↓, 1,   PDK1↓, 1,   PKM2↓, 2,   PPARγ↑, 1,   SIRT1↓, 1,   SIRT2↑, 1,  

Cell Death ⓘ

Akt↓, 7,   p‑Akt↓, 3,   APAF1↑, 1,   Apoptosis↑, 7,   BAD↑, 1,   Bak↑, 2,   BAX↑, 5,   Bax:Bcl2↑, 1,   Bcl-2↓, 8,   Bcl-xL↓, 2,   Casp↑, 1,   Casp1↓, 1,   Casp12↑, 1,   Casp3↑, 10,   Casp7↑, 2,   Casp8↑, 4,   Casp9↑, 8,   Cyt‑c↑, 7,   Diablo↑, 1,   DR4↑, 1,   DR5↑, 2,   Fas↑, 3,   FasL↑, 1,   HGF/c-Met↓, 1,   IAP1↓, 1,   IAP2↑, 1,   JNK↑, 3,   p‑JNK↑, 2,   MAPK↓, 3,   MAPK↑, 1,   Mcl-1↓, 2,   Mcl-1↑, 1,   p‑MDM2↓, 1,   Necroptosis↑, 1,   p27↑, 3,   p38↑, 1,   p‑p38↑, 2,   survivin↓, 5,   Telomerase↓, 2,   TumCD↑, 1,  

Kinase & Signal Transduction ⓘ

EF-1α↓, 1,   HER2/EBBR2↓, 1,   p70S6↓, 1,   Sp1/3/4↓, 1,  

Transcription & Epigenetics ⓘ

cJun↓, 1,   cJun↑, 1,   H3↓, 1,   H3↑, 1,   H4↓, 1,   H4↑, 1,   HATs↑, 1,   miR-21↓, 1,   other↑, 1,   other↝, 2,   tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 3,   cl‑CHOP↑, 1,   p‑eIF2α↑, 1,   ER Stress↑, 5,   GRP78/BiP↑, 2,   HSP27↓, 1,   HSP70/HSPA5↓, 1,   HSP70/HSPA5↑, 1,   HSP90↓, 2,   IRE1↑, 1,   UPR↑, 1,   XBP-1↑, 1,  

Autophagy & Lysosomes ⓘ

ATG5↑, 1,   LC3II↑, 2,   TumAuto↑, 2,  

DNA Damage & Repair ⓘ

CHK1↓, 1,   DNAdam↑, 6,   P53↑, 8,   PARP↑, 2,   cl‑PARP↑, 8,   PCNA↓, 3,  

Cell Cycle & Senescence ⓘ

CDK2↓, 3,   CDK4↓, 4,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 5,   cycE/CCNE↓, 1,   P21?, 1,   P21↑, 7,   p‑RB1↓, 2,   TumCCA↑, 12,  

Proliferation, Differentiation & Cell State ⓘ

CD133↓, 1,   CD34↓, 1,   cFos↓, 1,   cFos↑, 1,   CSCs↓, 3,   EMT↓, 7,   EMT↑, 1,   ERK↓, 4,   p‑ERK↓, 1,   FOXO3↑, 1,   FOXO4↑, 1,   GSK‐3β↓, 1,   HDAC↓, 2,   HDAC2↓, 1,   HDAC3↓, 1,   HH↓, 2,   miR-34a↑, 1,   mTOR↓, 8,   mTORC1↓, 2,   Nanog↓, 1,   Nestin↓, 1,   NOTCH↓, 1,   NOTCH1↓, 3,   NOTCH3↓, 2,   OCT4↓, 1,   PI3K↓, 5,   p‑PI3K↓, 1,   PTEN↓, 1,   PTEN↑, 3,   RAS↓, 1,   SOX2↓, 1,   p‑Src↓, 1,   STAT1↓, 1,   STAT3↓, 8,   STAT6↓, 1,   p‑STAT6↓, 1,   Wnt↓, 1,  

Migration ⓘ

5LO↓, 1,   AP-1↓, 1,   AXL↓, 1,   Ca+2↑, 4,   Cdc42↓, 1,   CEA↓, 1,   CLDN1↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 1,   FAK↓, 1,   p‑FAK↓, 1,   ITGB1↓, 2,   ITGB6↓, 1,   MET↓, 1,   p‑MET↓, 1,   MMP1↓, 1,   MMP13↓, 1,   MMP2↓, 5,   MMP9↓, 6,   MMPs↓, 2,   MUC4↓, 1,   N-cadherin↓, 3,   PKCδ↓, 1,   Rac1↓, 2,   Rho↓, 1,   Snail↓, 1,   SOX4↓, 1,   SOX4↑, 1,   TGF-β↓, 1,   TumCI↓, 5,   TumCMig↓, 5,   TumCP↓, 5,   TumMeta↓, 5,   Twist↓, 2,   Tyro3↓, 1,   uPA↓, 2,   Vim↓, 1,   Vim↑, 1,   Zeb1↓, 1,   ZO-1↑, 1,   α-tubulin↓, 1,   β-catenin/ZEB1↓, 3,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 6,   ATF4↑, 1,   ATF4↝, 1,   EGFR↓, 2,   EGFR↑, 1,   Hif1a↓, 6,   NO↑, 1,   TAMS↝, 1,   VEGF↓, 8,   VEGFR2↓, 2,  

Barriers & Transport ⓘ

GLUT1↓, 1,   P-gp↓, 4,   sonoP↑, 1,  

Immune & Inflammatory Signaling ⓘ

ASC↓, 1,   COX2↓, 6,   CXCR4↓, 2,   ICAM-1↓, 2,   IKKα↓, 2,   IL1↓, 1,   IL2↑, 1,   IL6↓, 4,   IL8↓, 2,   Inflam↓, 4,   IκB↓, 1,   NF-kB↓, 13,   p65↓, 2,   p‑p65↓, 2,   PD-1↓, 1,   PGE2↓, 2,   PSA↓, 2,   TNF-α↓, 2,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 3,   CDK6↓, 3,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 9,   BioAv↑, 10,   BioEnh↑, 1,   chemoR↓, 1,   ChemoSen↑, 13,   CYP1A2↑, 1,   CYP2A3/CYP2A6↓, 1,   Dose↓, 1,   Dose↑, 3,   Dose↝, 7,   eff↑, 17,   eff↝, 1,   Half-Life↓, 3,   Half-Life↝, 17,   MDR1↓, 3,   MRP1↓, 1,   P450↓, 1,   RadioS↑, 7,   selectivity↑, 10,  

Clinical Biomarkers ⓘ

AR↓, 3,   CEA↓, 1,   E6↓, 1,   E7↓, 1,   EGFR↓, 2,   EGFR↑, 1,   HER2/EBBR2↓, 1,   IL6↓, 4,   LDH↓, 1,   LDH↝, 1,   NSE↓, 1,   PSA↓, 2,  

Functional Outcomes ⓘ

AntiCan↓, 1,   AntiCan↑, 4,   AntiTum↑, 2,   cachexia↓, 1,   cardioP↑, 1,   chemoP↑, 4,   chemoPv↑, 1,   ChemoSideEff↓, 1,   hepatoP↑, 2,   neuroP↑, 1,   OS↑, 1,   radioP↑, 2,   RenoP↑, 1,   Risk↓, 1,   toxicity↝, 5,   TumVol↓, 1,  
Total Targets: 303

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 8,   Catalase↑, 4,   GPx↑, 4,   GPx1↑, 1,   GSH↑, 6,   GSTs↑, 4,   H2O2↓, 1,   H2O2↑, 1,   HDL↑, 1,   HO-1↑, 2,   Keap1↓, 1,   lipid-P↓, 3,   MDA↓, 4,   MPO↓, 2,   NADH↓, 1,   NRF2↑, 3,   RNS↓, 1,   ROS↓, 11,   SOD↑, 7,   SOD1↑, 1,   SOD2↑, 1,   TBARS↓, 1,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   AMPK↑, 1,   p‑cMyc↑, 1,   H2S↑, 1,   LDH↓, 2,   LDL↓, 1,   p‑PPARγ↓, 1,  

Cell Death ⓘ

Akt↓, 1,   BAX↓, 1,   Bcl-2↑, 1,   Casp3↓, 1,   iNOS↓, 1,   JNK↓, 1,   TRPV1↑, 1,  

Transcription & Epigenetics ⓘ

other↓, 1,   other↑, 3,   other↝, 1,  

DNA Damage & Repair ⓘ

DNArepair↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↓, 1,   ERK↑, 1,   IGF-1↓, 1,   IGFBP3↑, 1,   PI3K↓, 1,   STAT3↑, 1,  

Migration ⓘ

AntiAg↑, 3,  

Angiogenesis & Vasculature ⓘ

NO↓, 2,  

Barriers & Transport ⓘ

BBB↑, 2,   GastroP↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX1↓, 1,   COX2↓, 3,   IL10↑, 1,   IL18↓, 1,   IL1β↓, 2,   IL6↓, 2,   IL8↓, 1,   Imm↑, 1,   Inflam↓, 10,   NF-kB↓, 1,   NF-kB↑, 1,   PGE2↓, 1,   TNF-α↓, 4,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,   BChE↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 8,   BioAv↝, 3,   ChemoSen↑, 1,   Dose↑, 1,   Dose↝, 2,   eff?, 1,   eff↑, 4,   Half-Life↝, 10,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AST↓, 1,   BP↓, 2,   creat↓, 1,   GutMicro↑, 1,   IL6↓, 2,   LDH↓, 2,   NOS2↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   AntiDiabetic↑, 1,   cardioP↑, 5,   CardioT↓, 1,   chemoP↑, 1,   chemoPv↑, 3,   cognitive↑, 3,   hepatoP↑, 2,   memory↑, 1,   neuroP↑, 6,   Obesity↓, 1,   Pain↓, 1,   RenoP↑, 1,   toxicity↝, 1,   Weight↓, 1,  

Infection & Microbiome ⓘ

Bacteria↓, 1,  
Total Targets: 99

Scientific Paper Hit Count for: Half-Life, Half-Life
2 Allicin (mainly Garlic)
2 Ashwagandha(Withaferin A)
2 Fisetin
2 Resveratrol
2 Shikonin
2 Selenite (Sodium)
1 Betulinic acid
1 Capsaicin
1 Cannabichromene
1 Honokiol
1 itraconazole
1 Luteolin
1 Oleuropein
1 HydroxyTyrosol
1 Phenethyl isothiocyanate
1 Piperlongumine
1 Rosmarinic acid
1 SonoDynamic Therapy UltraSound
1 Silymarin (Milk Thistle) silibinin
1 Thymoquinone
1 Thymol-Thymus vulgaris
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:26  Cells:%  prod#:%  Target#:1109  State#:%  Dir#:4
  wNotes=0  sortOrder:rid,rpid

 

Home Page